In conclusion, this model, despite its limitations and early development state, provides a bone compartment and a niche to support the engraftment of CD34+ cells from healthy and possibly diseased marrow patients, with the potential to also engraft tumour cells, making it a promising platform in the future of cancer preclinical research. This evidence concerns the gene CD34 and neoplasm.